Neuren Pharmaceuticals Ltd has released a press release.
Appendix 4E and 2024 full year accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- DAYBUE (trofinetide) 2024 net sales US$348 million
- Neuren receives Rare Pediatric Disease Designation from FDA
- Fast Track granted by FDA for NNZ-2591 in Pitt Hopkins
- Priority Review Voucher sale proceeds received
- Trofinetide marketing application submitted in Europe
Later from Neuren Pharmaceuticals
- 2024 results - A$166m comprehensive income for shareholders
- Neuren receives DAYBUE sales milestone payment of US$50m
- Neuren initiates development of NNZ-2591 to treat HIE
- NEU confirms primary endpoints for Phase 3 trial in PMS
- DAYBUE Q1 2025 net sales US$84.6m up 11% from Q1 2024
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals